2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1163

Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Abstract Number: 2258

Risk Factors for Total Joint Replacement in Systemic Lupus Erythematosus Patients with Avascular Necrosis
Abstract Number: 1989

Risk Factors for Vertebral Fractures in Patients with Rheumatoid Arthritis – the Tomorrow Study –
Abstract Number: 707

Risk of Cancer in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies
Abstract Number: 1990

Risk of Falling Is Equivalent Between Patients with Rheumatoid Arthritis and Healthy Individuals – the Tomorrow Study-
Abstract Number: 922

Risk of Fracture Among Treated and Untreated Men with Osteoporosis
Abstract Number: 2147

Risks to Visit Emergency Room in Patients with Rheumatoid Arthritis: A Two-Year Retrospective Study
Abstract Number: 449

Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Abstract Number: 2383

Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients
Abstract Number: 1543

Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Trials
Abstract Number: 285

Rituximab for Severe Disease Flares in Childhood ANCA Vasculitides
Abstract Number: 464

Rituximab for Treatment of Rheumatoid Arthritis: Treatment Effectiveness in the Corrona Database
Abstract Number: 2596

Rituximab Treatment for Antineutrophil Cytoplasmic Antibody – Associated Vasculitis in Children
Abstract Number: 1299

Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study
Abstract Number: 1652

Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].